Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

NEW YORK (AP) — More U.S. children have died this flu season than at any time since the swine flu pandemic 15 years ago, ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

NEW YORK (AP) — Tim Friede has been bitten by snakes hundreds of times — often on purpose. Now scientists are studying his ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Here are Investing.com’s stocks of the week. Microsoft was one of many tech giants that reported earnings this week, with the company topping profit and revenue expectations. MSFT shares jumped more ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.